National Institute of Allergy and Infectious Diseases (NIAID): all 2,445 studies

Page 3 of 25. Open to participants first (182), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetic Study of IV Artesunate to Treat Children With Severe MalariaCompletedNCT05750459Phase 4Results posted
• A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for MpoxCompletedNCT05740982Phase 2Results posted
• Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRCCompletedNCT05734508Phase 4Results posted
• Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIATerminatedNCT05710640Phase 2Results posted
• Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)CompletedNCT05645757Phase 1Results posted
• A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIVCompletedNCT05630885Phase 2Results posted
• Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated TuberculosisCompletedNCT05630872Phase 2Results posted
• A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy AdultsCompletedNCT05627258Phase 1Results posted
• Safety of Intravenous Apramycin in AdultsCompletedNCT05590728Phase 1Results posted
• Siplizumab in T1DMTerminatedNCT05574335Phase 1/2Results posted
• Tecovirimat for Treatment of Monkeypox VirusCompletedNCT05559099Phase 2Results posted
• Study of Tecovirimat for Human Mpox VirusTerminatedNCT05534984Phase 3Results posted
• COVID Protection After Transplant - Sanofi GSK (CPAT-SG) StudyCompletedNCT05518487Phase 2Results posted
• Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox VaccineCompletedNCT05512949Phase 2Results posted
• Safety and Immunogenicity of CJCV2 With and Without ALFQCompletedNCT05500417Phase 1Results posted
• A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy AdultsTerminatedNCT05470400Phase 1Results posted
• Neonatal Phase 1 Valacyclovir StudyCompletedNCT05468619Phase 1Results posted
• A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas AeruginosaCompletedNCT05453578Phase 1/2Results posted
• Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin AnalysisCompletedNCT05436535Phase 4Results posted
• A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1CompletedNCT05406583Phase 1Results posted
• Anti-malaria MAb in Kenyan ChildrenCompletedNCT05400655Phase 2Results posted
• Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy AdultsCompletedNCT05398796Phase 1Results posted
• Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic LupusTerminatedNCT05306873Phase 2Results posted
• CD40L Antagonism in Rheumatoid Arthritis (RA)TerminatedNCT05306353Phase 2Results posted
• Anti-malaria MAb in Malian ChildrenCompletedNCT05304611Phase 2Results posted
• Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy AdultsCompletedNCT05292391Phase 1Results posted
• COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)CompletedNCT05289037Phase 2Results posted
• A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult ParticipantsActive, not recruitingNCT05217641Phase 1Results posted
• A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult ParticipantsCompletedNCT05184452Phase 1Results posted
• Targeted Investigation of Microbiome EliminationTerminatedNCT05177328Phase 1Results posted
• Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in MaliCompletedNCT05135273Phase 1Results posted
• Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)CompletedNCT05123222Phase 1Results posted
• Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)CompletedNCT05099965Phase 2Results posted
• Blood-Stage Plasmodium Vivax Cell BankCompletedNCT05095272Phase 1Results posted
• COVID Protection After Transplant-Immunosuppression ReductionCompletedNCT05077254Phase 2Results posted
• An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 ChallengeCompletedNCT05048875Phase 2Results posted
• Evaluation of Tofacitinib in Prevention of Photosensitivity in LupusCompletedNCT05048238Phase 1Results posted
• Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza VaccineCompletedNCT05027932Phase 1Results posted
• Trial to Evaluate L9LS in Healthy AdultsCompletedNCT05019729Phase 1Results posted
• Linezolid Dosing Strategies in Drug-Resistant TBCompletedNCT05007821Phase 2Results posted
• COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedNCT05000216Phase 2Results posted
• ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19CompletedNCT04988035Phase 2Results posted
• Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza StrainCompletedNCT04978454Phase 1Results posted
• The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial DoseCompletedNCT04977479Phase 2Results posted
• COVID-19 Protection After Transplant Pilot StudyCompletedNCT04969263Phase 2Results posted
• Vaccination for Recovered Inpatients With COVID-19 (VATICO)CompletedNCT04969250Phase 4Results posted
• Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza VaccineTerminatedNCT04960397Phase 1Results posted
• SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent VaccineCompletedNCT04952402Phase 4Results posted
• Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)TerminatedNCT04918147Phase 2Results posted
• Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.CompletedNCT04915768Phase 1Results posted
• First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy AdultsCompletedNCT04896086Phase 1Results posted
• Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA VaccinesCompletedNCT04889209Phase 1/2Results posted
• Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)CompletedNCT04870138Phase 1Results posted
• COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and DysregulationsCompletedNCT04852276Results posted
• ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19CompletedNCT04843761Phase 3Results posted
• A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.TerminatedNCT04840199Phase 2Results posted
• A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in KenyaCompletedNCT04826094Phase 1Results posted
• Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent FemalesCompletedNCT04824131Phase 2Results posted
• A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 VaccineCompletedNCT04811664Phase 3Results posted
• Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated AdultsCompletedNCT04785144Phase 1Results posted
• Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy AdultsCompletedNCT04776317Phase 1Results posted
• DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus BacteremiaCompletedNCT04775953Phase 2Results posted
• COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 VaccinationsCompletedNCT04761822Phase 2Results posted
• Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB VaccinationCompletedNCT04722003Phase 2Results posted
• Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent MalesCompletedNCT04692077Phase 2Results posted
• Anthrax AV7909 Liquid vs LyophilizedCompletedNCT04660201Phase 1Results posted
• Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy AdultsCompletedNCT04645147Phase 1Results posted
• Adaptive COVID-19 Treatment Trial 4 (ACTT-4)CompletedNCT04640168Phase 3Results posted
• ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19CompletedNCT04583969Phase 2Results posted
• ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19CompletedNCT04583956Phase 2Results posted
• PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the USCompletedNCT04582266Results posted
• Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy AdultsCompletedNCT04579250Phase 1Results posted
• Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of AgeCompletedNCT04520659Phase 1Results posted
• ACTIV-2: A Study for Outpatients With COVID-19CompletedNCT04518410Phase 2/3Results posted
• Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and PostpartumTerminatedNCT04518228Results posted
• Grass Pollen Immunotherapy Plus Dupilumab for Tolerance InductionCompletedNCT04502966Phase 2Results posted
• Adaptive COVID-19 Treatment Trial 3 (ACTT-3)CompletedNCT04492475Phase 3Results posted
• Phase 1 Study of SAR440894 vs PlaceboCompletedNCT04441905Phase 1Results posted
• Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and CambodiaCompletedNCT04434846Results posted
• A Phase 1 Trial to Evaluate CAP256V2LS in Healthy AdultsCompletedNCT04408963Phase 1Results posted
• Adaptive COVID-19 Treatment Trial 2 (ACTT-2)CompletedNCT04401579Phase 3Results posted
• COVID-19 and Anti-CD14 Treatment TrialTerminatedNCT04391309Phase 2Results posted
• COVID-19: Human Epidemiology and Response to SARS-CoV-2CompletedNCT04375761Results posted
• Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19TerminatedNCT04358068Phase 2Results posted
• Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in CambodiaCompletedNCT04350905Phase 1Results posted
• Evaluation of AMG 714 for VitiligoCompletedNCT04338581Phase 2Results posted
• Safety and Efficacy of CIS43LS Anti-malaria mAb in MaliCompletedNCT04329104Phase 2Results posted
• Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST StudyTerminatedNCT04311502Phase 2Results posted
• Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)CompletedNCT04283461Phase 1Results posted
• Adaptive COVID-19 Treatment Trial (ACTT)CompletedNCT04280705Phase 3Results posted
• Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected IndividualsTerminatedNCT04272242Phase 2Results posted
• Phase 2 Shigella Vaccine and ChallengeCompletedNCT04242264Phase 2Results posted
• Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)CompletedNCT04216589Phase 2Results posted
• Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult ParticipantsCompletedNCT04212091Phase 1Results posted
• Safety and Pharmacokinetics of VT-1598CompletedNCT04208321Phase 1Results posted
• Trial to Evaluate CIS43LS in Healthy AdultsCompletedNCT04206332Phase 1Results posted
• B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-BCompletedNCT04193189Phase 3Results posted
• Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected AdultsCompletedNCT04177355Phase 1Results posted
• Phase I Norovirus Challenge ModelCompletedNCT04174560Phase 1Results posted
• Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant PairsCompletedNCT04140266Phase 3Results posted

← National Institute of Allergy and Infectious Diseases (NIAID) overview and focus areas